Real longs here aren't hoping the SP will hold at $0.63. Their investment strategy is based on the fact that BPs are interested in drugs (not SP) and IPIX has multiple promising candidates.
For example, B-UP completed a Phase 2 POC trial with 67% clinical remission with endoscopic images. BPs are showing strong interests in IBD drugs with several blockbuster deals in the past 12 months. There was a deal where J&J invested $990M with $50M upfront for a preclinical IBD drug.
To show partnership is unlikely you need to show why BPs aren't interested in IBD drugs or why B-UP's clinical data aren't good enough. An example to support your argument would be there's no partnership in IBD drugs recently. Hope you can find one.
Market Data 
Markets 
AI
